A Comparative Evaluation Of Efficacy Of Intralesional Placental Extract And Triamcinolone Acetonide In Patients With Osmf

Dr. Doyel Roy¹, Dr. Kumar H², Dr. Jugajyot iPathi³, Dr. Srikar MV⁴, Dr. Neha Kriti⁵, Dr. Vidya K.C.⁶

¹Senior Lecturer, Dept of Oral Medicine & Radiology, Dr. HSRSM Dental College & Hospital, Maharastra University of Health & Science

²Professor & Head Dept of Oral & Maxillofacial Pathology, Kalinga Institute of Dental Sciences, KIIT Deemed to be University, Bhubaneswar

³Reader, Dept of Oral & Maxillofacial Surgery, Kalinga Institute of Dental Sciences, KIIT Deemed to be University, Bhubaneswar

⁴Professor & Head Dept of Oral & Maxillofacial Surgery, Kalinga Institute of Dental Sciences, KIIT Deemed to be University, Bhubaneswar

⁵Post Graduate Trainee, Dept of Oral & Maxillofacial Surgery, Kalinga Institute of Dental Sciences, KIIT Deemed to be University, Bhubaneswar

⁶Professor, Dept of Oral & Maxillofacial Surgery, Kalinga Institute of Dental Sciences, KIIT Deemed to be University, Bhubaneswar

Abstract

Aim: To compare intralesional placental extract and triamcinolone acetonide in patients with OSMF.

Materials & Methods: Group I patients were given 1 ml of 40mg/ml triamcinolone acetonide and group II patients were administered 2 ml intralesional injections of aqueous placental extract on both buccal mucosa at weekly intervals for 10 weeks. Parameters such as burning sensation, pain (VAS), tongue protrusion, mouth opening and cheek flexibility were recorded pre-operatively and on follow up visits. Each group had 16 patients.

Results: Both groups showed reduction in burning sensation, pain (VAS) and improvement in mouth opening, cheek flexibility and tongue protrusion.

Conclusion: Intralesional injection of triamcinolone acetonide found to be superior than placental extract in patients with OSMF.

Key words: Oral submucous fibrosis, triamcinolone acetonide, placental extract
Introduction

Oral submucous fibrosis (OSMF) is one of the potentially malignant disorders, earlier classified under premalignant condition. It is a crippling disease leading to great difficulties in patient’s daily habits such as swallowing, speaking and talking. The clinical presentation of the disease can be observed under three stages viz, stage of stomatitis and vesiculation, stage of ulceration and stage of complications and sequelae.

The peculiar feature of this disease is occurrence of burning sensation to spicy food. Presence of vertical fibrotic bands especially on buccal mucosa bilaterally helps in diagnosis of the disease. The mucosa loose its elasticity and become fibrotic. Fibrosis is also seen on labial mucosa, tongue, lips, soft palate etc. Uvula become fibrotic, shrunken and hockey stick like. Lips become leathery and difficult to evert. Cases are classified into mild, moderate, moderately advance and severely advanced based on clinical features of burning sensation, tongue protrusion, mouth opening etc.

Slight male predilection has been seen since the habit of arecanut which is the main causative agent is commonly encountered in males. Part form arecanut, tobacco, genetic predisposition, nutrition deficiency etc. also plays an important role.

Different treatment modalities have resulted less or more improvement in patient condition. A successful treatment outcome in measured in terms in improvement in mouth opening (normal 35-50 mm), tongue protrusion and cheek flexibility. In most of the cases, treatment starts with topical steroid such as triamcinolone acetonide. However, in severe cases, systemic steroids are recommended. Few prefer intralesional placental extract which also found to be effective. Considering this, we select both these drugs such as intralesional placental extract and triamcinolone acetonide and treatment outcomes were compared.

Methodology

A total of thirty- two adult patients in age ranged 18-46 years irrespective of sex were selected for this prospective, single blinded observational study. Enrolled patients were made aware of the importance of the study and after convincing them, a written consent was obtained in vernacular language. Helsinki’s guidelines were followed for the study and research and review committee approval was sorted before commencing the study. Inclusion criteria were grade II and III OSMF patients, those which fall within specified age group and giving consent. Exclusion criteria were patients on any kind of medication and pregnant women.

A simple stratified random sampling technique was followed for grouping the patients. Group I patients were given 1 ml of 40mg/ml triamcinolone acetonide and group II patients were administered 2 ml intralesional injections of aqueous placental extract on both buccal mucosa at weekly intervals for 10 weeks. Parameters such as burning sensation, pain (VAS), tongue protrusion, mouth opening and cheek flexibility were recorded pre- operatively and on follow up visits. Mann Whitney U test was used for comparison of parameters between both groups setting level of significance below 0.05 as significant.

Results

The mean value of burning sensation in group I at baseline was 68.2, at 5 weeks was 40.6 and at 10 weeks was 24.8. In group II, it was 66.8, 48.5 and 32.6 at baseline, 5 weeks and 10 weeks
respectively. A significant difference was observed on intergroup and intragroup comparison (P<0.05) (Table 1).

The mean value of pain (VAS) in group I at baseline was 54.0, at 5 weeks was 42.3 and at 10 weeks was 30.6. In group II, it was 56.4, 48.2 and 32.8 at baseline, 5 weeks and 10 weeks respectively. A significant difference was observed on intragroup comparison (P<0.05) (Table 2).

The mean value of mouth opening (mm) in group I at baseline was 20.4, at 5 weeks was 26.8 and at 10 weeks was 30.5. In group II, at baseline it was 21.4, at 5 weeks was 27.6 and at 10 weeks was 31.6. A significant difference was observed on intragroup comparison (P<0.05) (Table 3).

The mean value of cheek flexibility (mm) in group I at baseline was 0.87, at 5 weeks was 0.92 and at 10 weeks was 0.96. In group II, at baseline it was 0.90, at 5 weeks was 0.95 and at 10 weeks was 1.04. A significant difference was observed on intragroup and intergroup comparison (P<0.05) (Table 4).

The mean value of tongue protrusion (mm) in group I at baseline was 3.08, at 5 weeks was 3.26 and at 10 weeks was 3.41. In group II, at baseline it was 3.12, at 5 weeks was 3.36 and at 10 weeks was 3.71. A significant difference was observed on intragroup and intergroup comparison (P<0.05) (Table 5).

Discussion

OSMF is one of the potential malignant disorders of middle age population with male predominance. It is also considered as collagen vascular disease. The main concern of the patient is severe burning sensation, restricted tongue movement and dysphagia. The progressive nature of the disease poses difficulty in complete cure. Not a single treatment modality such as physiotherapy, drugs and surgical intervention have been cure disease completely. Nowadays, soft tissues laser is being widely used. In present study we compared intralesional triamcinolone with intralesional injection of placental extract.

Our study found a significant difference in reduction in burning sensation on intergroup and intragroup comparison. The mean value of burning sensation in group I at baseline was 68.2, at 5 weeks was 40.6 and at 10 weeks was 24.8. In group II, it was 66.8, 48.5 and 32.6 at baseline, 5 weeks and 10 weeks respectively. Shinde et al in their study enrolled 40 grade II and III OSMF patients who received either triamcinolone acetonide or placental extract in the lesion on right and left buccal mucosa. It was found that there were significant reductions in pain, burning sensation, increase in mouth opening, tongue protrusion and cheek flexibility. However, triamcinolone acetonide resulted better outcome of treatment.

We found that the mean value of pain (VAS) in group I at baseline was 54.0, at 5 weeks was 42.3 and at 10 weeks was 30.6. In group II, it was 56.4, 48.2 and 32.8 at baseline, 5 weeks and 10 weeks respectively. It was found that the mean value of mouth opening (mm) in group I at baseline was 20.4, at 5 weeks was 26.8 and at 10 weeks was 30.5. In group II, at baseline it was 21.4, at 5 weeks was 27.6 and at 10 weeks was 31.6. A significant reduction in pain on VAS scale was observed in both groups. Naik et al conducted a study in which 30 patients of OSMF received combination of triamcinolone acetonide and hyaluronidase and 30 patients received placentrex injection intralesionally for 8 weeks. Authors found that combination treatment were ore effective in
improving mouth opening, tongue protrusion and cheek flexibility as compared to placentrex injection alone.

We observed that there was improvement in cheek flexibility as well as tongue protrusion in both groups. Yadav et al\textsuperscript{16} in their study on 30 OSMF patients received combination of triamcinolone acetonide, hyaluronidase and oral physiotherapy exercise for mouth opening and cheek flexibility and found significant improvement in all parameters. Samuel et al\textsuperscript{17} conducted a study on 75 patients of OSMF in which group A patients received weekly intralesional triamcinolone (40 mg/ml) injections, group B received oral lycopene 6 mg daily, and group C received both weekly steroid injection and oral lycopene for 2 months respectively. It was observed that mouth opening values for the patients showed a mean increase of 6.56 mm, 3.04 mm and 7.56 mm in Groups A, B and C, respectively. Lycopene showed an early reduction in the burning sensation with a mean score of 4.8 in group B by the 1st week itself which was highly significant.

The shortcoming of the study is small sample size and short follow up. Only 2 drugs were compared in our study.

**Conclusion**

Intralesional injection of triamcinolone acetonide found to be superior than placental extract in patients with OSMF.

Source of funding: Self

Conflict of interest: Nil

**References**


**Legends for illustration**

**Table**

**Table 1: Comparison of burning sensation between both groups**

<table>
<thead>
<tr>
<th>Time interval</th>
<th>Group I</th>
<th>Group II</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>68.2</td>
<td>66.8</td>
<td>0.81</td>
</tr>
<tr>
<td>5 weeks</td>
<td>40.6</td>
<td>48.5</td>
<td>0.90</td>
</tr>
<tr>
<td>10 weeks</td>
<td>24.8</td>
<td>32.6</td>
<td>0.05</td>
</tr>
<tr>
<td>P value</td>
<td>0.02</td>
<td>0.01</td>
<td></td>
</tr>
</tbody>
</table>

Mann Whitney U test, Significance, P< 0.05
Table 2: Comparison of pain between both groups

<table>
<thead>
<tr>
<th>Time interval</th>
<th>Group I</th>
<th>Group II</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>54.0</td>
<td>56.4</td>
<td>0.94</td>
</tr>
<tr>
<td>5 weeks</td>
<td>42.3</td>
<td>46.2</td>
<td>0.86</td>
</tr>
<tr>
<td>10 weeks</td>
<td>30.6</td>
<td>32.8</td>
<td>0.71</td>
</tr>
<tr>
<td>P value</td>
<td>0.04</td>
<td>0.05</td>
<td></td>
</tr>
</tbody>
</table>

Mann Whitney U test, Significance, P< 0.05

Table 3: Comparison of mouth opening(mm) between both groups

<table>
<thead>
<tr>
<th>Time interval</th>
<th>Group I</th>
<th>Group II</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>20.4</td>
<td>21.4</td>
<td>0.92</td>
</tr>
<tr>
<td>5 weeks</td>
<td>26.8</td>
<td>27.6</td>
<td>0.98</td>
</tr>
<tr>
<td>10 weeks</td>
<td>30.5</td>
<td>31.6</td>
<td>0.82</td>
</tr>
<tr>
<td>P value</td>
<td>0.03</td>
<td>0.04</td>
<td></td>
</tr>
</tbody>
</table>

Mann Whitney U test, Significance, P< 0.05

Table 4: Comparison of cheek flexibility(mm) between both groups

<table>
<thead>
<tr>
<th>Time interval</th>
<th>Group I</th>
<th>Group II</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>0.87</td>
<td>0.90</td>
<td>0.97</td>
</tr>
<tr>
<td>5 weeks</td>
<td>0.92</td>
<td>0.95</td>
<td>0.82</td>
</tr>
<tr>
<td>10 weeks</td>
<td>0.96</td>
<td>1.04</td>
<td>0.05</td>
</tr>
<tr>
<td>P value</td>
<td>0.05</td>
<td>0.02</td>
<td></td>
</tr>
</tbody>
</table>

Mann Whitney U test, Significance, P< 0.05

Table 5: Comparison of tongue protrusion(cm) between both groups

<table>
<thead>
<tr>
<th>Time interval</th>
<th>Group I</th>
<th>Group II</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>3.08</td>
<td>3.12</td>
<td>0.84</td>
</tr>
<tr>
<td>5 weeks</td>
<td>3.26</td>
<td>3.36</td>
<td>0.71</td>
</tr>
<tr>
<td>10 weeks</td>
<td>3.41</td>
<td>3.71</td>
<td>0.05</td>
</tr>
<tr>
<td>P value</td>
<td>0.03</td>
<td>0.01</td>
<td></td>
</tr>
</tbody>
</table>

Mann Whitney U test, Significance, P< 0.05